Clin2
NCT06115642Possibly a fitEnrolling by invitation

Study of HLX43 for advanced solid tumors

Advanced/Metastatic Malignant Solid Tumors

Treatments studied

Part of Cancer clinical trials.

This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
367 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have an advanced solid tumor that has not improved with standard therapies or has no standard treatment available.
  • You have at least one tumor that can be measured on scans.
  • You are able to do your daily activities without help (ECOG score 0 or 1).
  • You have not had certain cancer treatments within specific time frames before starting this study.
  • You have adequate organ function (kidneys, liver, blood counts) as shown by lab tests.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06907615Recruiting· Phase 2
Study of HLX43 for advanced non-small cell lung cancer

This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.

Houston, Texas
NCT07274813Recruiting· Early Phase 1
Study of HLX37 for advanced solid tumors that haven't responded to treatment

This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.

Shanghai
NCT07473726Recruiting· Phase 1
Study of a new drug for advanced solid tumors

This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.

North Ryde, New South Wales
NCT06210815Recruiting· Phase 1
Testing a new drug HLX42 for advanced solid tumors

This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.

Guangdong, Guangzhou
NCT07253142Recruiting· Phase 2
Study of HLX43 with Serplulimab for advanced lung cancer

This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.

Hefei, Anhui
NCT06857279Recruiting· Phase 2
Testing HLX43 for advanced head and neck cancer

This trial tests an investigational drug called HLX43 for people with advanced head and neck cancer that has returned or spread. It aims to see if the drug can shrink tumors or slow cancer growth.

Jinan, Shandong

Hear when a new Advanced/Metastatic Malignant Solid Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.